ZBIO Share Price Performance
US$20.85
3.16 (17.86%)
Price US$20.85
Share PriceUS$20.85
Zenas BioPharma, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
ZBIO Community Narratives
There are no narratives available yet.
Zenas BioPharma, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -4.20
- Gross Margin
- -970.86%
- Net Profit Margin
- -1,180.05%
- Debt/Equity Ratio
- 0%
Zenas BioPharma, Inc. Competitors
Snowflake Analysis
About ZBIO
- Founded
- 2019
- Employees
- 130
- CEO
- WebsiteView website
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 1.1%
- 3 Months: 8.9%
- 1 Year: 18.9%
- Year to Date: 15.1%
The market is up 1.1% over the last week, with the Information Technology sector leading the way, up 1.9%. In the last year, the market has climbed 19%. Earnings are forecast to grow by 15% annually. Market details ›